HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …
Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for advanced breast cancer: targeted drug duo enters final testing phase
Disease control Recruiting nowThis study tests a new combination of two drugs (saruparib and camizestrant) against standard treatments for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people with inherited BRCA1, BRCA2, or PALB2 mutations. The goal is to see if the new…
Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Promising combo tackles Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how s…
Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC